Introduction and hypothesis
In this study, we planned to explore the effects of sodium bicarbonate orally (NaHCO3) treatment on female patients with lower urinary tract symptoms (LUTS) who have acidic urine pH values (<6).
NaHCO3 was given orally to 33 female patients for 4 weeks at a dose of 2 × 4 g/day. Laboratory values, bladder diary, the Patient Perception of Bladder Condition Score (PPBC), Patient Perception of Intensity of Urgency Scale (PPIUS), Overactive Bladder–Validated 8-question Awareness tool (OAB-V8), Pelvic Pain and Urgency & Frequency Patient Symptom Scale tests (PUFSS), and the King’s Health Questionnaire (KHQ) scores before and after treatment were compared.
A significant increase was detected in urine pH values measured after treatment (5.31 ± 0.52 to 7.2 ± 0.66, p < 0.001), but not in blood pH values (7.369 ± 0.33 to 7.384 ± 0.28, p = 0.14). After treatment, a significant decrease was detected in daily frequency, nocturia, urgency, and urge incontinence prevalence (p < 0.001,p = 0.003, p < 0.001, p = 0.002, respectively) and PPBC, PPIUS, PUFSS, and OAB-V8 symptom scores (p = 0.004, p = 0.002, p < 0.001, p < 0.001, respectively). A significant decrease was detected in all KHQ subunit scores.
Urine alkalinization with NaHCO3 orally in female patients with LUTS and acidic urine pH has a significant level of positive effects on symptoms and symptom scores. Our results show that this new treatment modality—which is inexpensive, easy to use, and has a low side-effect profile is effective in this chronic patient group.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Varella LR, Bezerra da Silva R, Eugênia de Oliveira MC, Melo pH, Maranhão TM, Micussi MT. Assessment of lower urinary tract symptoms in different stages of menopause. J Phys Ther Sci. 2016;28(11):3116–21.
Denys MA, Anding R, Tubaro A, Abrams P, Everaert K. Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Neurourol Urodyn. 2016;35(2):278–82.
Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.
Bilge C, Beji NK. Life quality scales used for evaluating Urinar symptoms in women. J Female Funct Urol. 2015;1-4:41–5.
Sanford MT, Rodriguez LV. The role of environmental stress on lower urinary tract symptoms. Curr Opin Urol. 2017;27(3):268–73.
Zhang HL, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT. Tamsulosin for treatment of lower urinary tract symptoms in women:a systematic review and meta-analysis. Int J Impot Res. 2017;29(4):148–56.
Cox L, Rovner ES. Lower urinary tract symptoms in women: epidemiology, diagnosis, and management. Curr Opin Urol. 2016;26(4):328–33.
Canda AE, Cross CR, Chapple CR. Pharmacology of the lower urinary tract and Management of Overactive Bladder. J Turkish-German Gynecol Assoc. 2006;7:146–57.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. American urological association; Society of Urodynamics, female pelvic medicine. J Urol. 2015;193(5):1572–80.
Yi JH, Shin HJ, Kim SM, Han SW, Kim HJ, Oh MS. Does the exposure of urine samples to air affect diagnostic tests for urine acidification? Clin J Am Soc Nephrol. 2012;7(8):1211–6.
Demirbas A, Sarici H, Kilinc MF, Telli O, Ozgur BC, Doluoglu OG, et al. The relationship between acidic urinary pH and overactive bladder; alkalization of urine improves the symptoms of overactive bladder. Urol Int. 2015;95(2):223–6.
Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG. A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol Res. 2001;29:295–302.
Kobayashi H, Yoshiyama M, Zakoji H, Takeda M, Araki I. Sex differences in the expression profile of acid-sensing ion channels in the mouse urinary bladder: a possible involvement in irritative bladder symptoms. BJU Int. 2009;104:1746–51.
Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev. 2009;60(1):267–77.
Sánchez-Freire V, Blanchard MG, Burkhard FC, Kessler TM, Kellenberger S, Monastyrskaya K. Acid-sensing channels in human bladder: expression, function and alterations during bladder pain syndrome. J Urol. 2011;186(4):1509–16.
Munday PE. Cymalon in the management of urinary tract symptoms. Genitourin Med. 1990;66(6):460–2.
Brumfitt W, Hamilton-Miller JM, Cooper J, Raeburn A. Relationship of urinary pH to symptoms of 'cystitis'. Postgrad Med J. 1990;66(779):727–9.
Hohlbrugger G, Lentsch P. Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder, and this is more pronounced after DMSO exposure. Eur Urol. 1985;11(2):127–30.
Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int. 2012;109(11):1584–91.
Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1–26.
Cohen B, Laish I, Brosh-Nissimov T, Hoffman A, Katz LH, Braunstein R, et al. Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial. Am J Emerg Med. 2013;31(12):1703–6.
Takahashi S, Takei M, Nishizawa O, Yamaguchi O, Kato K, Gotoh M, et al. Clin Guid Female Lower Urinary Tract Symp. 2016;8(1):5–29.
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012 Dec;110(11):1767–74.
Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.
Yoshimura N. Underlying mechanisms of interstitial cystitis/painful bladder syndrome (IC/PBS). Nishinihon J Urol. 2009;71(6):243–52.
Ueda T, Yoshida T, Tanoue H, Ito M, Tamaki M, Ito Y, et al. Urine alkalization improves the problems of pain and sleep in hypersensitive bladder syndrome. Int J Urol. 2014;21(5):512–7.
Tolouian R, Wild D, Lashkari MH, Najafi I. Oral alkalinizing solution as a potential prophylaxis against myoglobinuric acute renal failure: preliminary data from healthy volunteers. Nephrol Dial Transplant. 2005;20(6):1228–31.
The authors received no financial support for the research, authorship, and/or publication of this article.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent was received from Necmettin Erbakan University Meram Faculty of Medicine ethics committee before the study (No: 2017/981).
Conflicts of interest
About this article
Cite this article
Sönmez, M.G., Göğer, Y.E., Ecer, G. et al. Effects of urine alkalinization with sodium bicarbonate orally on lower urinary tract symptoms in female patients: a pilot study. Int Urogynecol J 29, 1029–1033 (2018). https://doi.org/10.1007/s00192-017-3492-3
- Urine alkalinization
- Sodium bicarbonate orally
- Lower urinary tract symptoms
- Urine pH